-
公开(公告)号：EP2930167B1
公开(公告)日：2018-11-21
申请号：EP13860630.6
申请日：2013-12-06
发明人： LO, Hoyin , WANG, Aichen , ZHANG, Qian
IPC分类号： A61K31/4045 , A61K31/4155 , A61K31/4196 , A61K31/433 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D209/30 , C07D409/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D498/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12
CPC分类号： A61K31/496 , A61K31/4045 , A61K31/4155 , A61K31/4196 , A61K31/433 , A61K31/435 , A61K31/438 , A61K31/439 , A61K31/4439 , A61K31/454 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D209/30 , C07D209/34 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D471/14 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/107 , C07D498/04 , A61K2300/00 , A61K31/404 , A61K31/4192 , A61K31/427 , A61K31/422
摘要： The present invention relates to a compound represented by general formula (I), a method for preparing said compound, a pharmaceutical formulation containing said compound, and the use of said compound in manufacture of a medicament for treating or preventing the fibrous degeneration disease and treating the excessive proliferation disease: wherein ring A, X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , a, b and n are defined as those in the description.
-
2.发明公开INDOLE FULL KETONE DERIVATIVE USED AS TYROSINE-KINASE INHIBITOR 审中-公开ALS TYROSINKINASEHEMMER VERWENDETES VOLLSTNDNDES INDOLKETONDERIVAT
公开(公告)号：EP2930167A1
公开(公告)日：2015-10-14
申请号：EP13860630.6
申请日：2013-12-06
发明人： LO, Hoyin , WANG, Aichen , ZHANG, Qian
IPC分类号： C07D209/34 , C07D487/10 , C07D487/08 , C07D403/12 , C07D403/14 , C07D471/10 , C07D471/14 , C07D401/14 , C07D401/12 , C07D491/107 , C07D405/12 , C07D405/14 , C07D417/14 , A61K31/404 , A61K31/4995 , A61K31/438 , A61K31/435 , A61K31/439 , A61K31/4439 , A61K31/506
CPC分类号： A61K31/496 , A61K31/4045 , A61K31/4155 , A61K31/4196 , A61K31/433 , A61K31/435 , A61K31/438 , A61K31/439 , A61K31/4439 , A61K31/454 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D209/30 , C07D209/34 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D471/14 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/107 , C07D498/04 , A61K2300/00 , A61K31/404 , A61K31/4192 , A61K31/427 , A61K31/422
摘要： The present invention relates to a compound represented by general formula (I), a method for preparing said compound, a pharmaceutical formulation containing said compound, and the use of said compound in manufacture of a medicament for treating or preventing the fibrous degeneration disease and treating the excessive proliferation disease:
wherein ring A, X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , a, b and n are defined as those in the description.摘要翻译： 本发明涉及由通式（I）表示的化合物，所述化合物的制备方法，含有所述化合物的药物制剂，以及所述化合物在制备用于治疗或预防纤维变性疾病和治疗 过度增生疾病：其中环A，X，R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8，R 9，a，b和n定义为说明书中的那些 。
-
3.发明公开
公开(公告)号：EP2607363A4
公开(公告)日：2014-01-22
申请号：EP11817649
申请日：2011-08-18
发明人： HUANG ZHENHUA , WANG JINYUAN , ZHANG DEDONG
IPC分类号： C07D471/04 , A61K31/437 , A61K31/4745 , A61K31/4985 , A61K31/5365 , A61P9/12 , A61P13/12
CPC分类号： A61K31/4745 , A61K31/381 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/407 , A61K31/417 , A61K31/437 , A61K31/496 , A61K31/4985 , A61K31/517 , A61K31/5365 , A61K31/5377 , A61K31/541 , A61K38/1709 , A61K45/06 , C07D471/04 , C07D487/04 , A61K2300/00
摘要： The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y 1 , Y 2 , Y 3 , R 1 , R 2a ,R 2b , R 3a , R 3b , R 4 , Cy and n are as presented in the description.
-
公开(公告)号：EP2607363B1
公开(公告)日：2019-02-27
申请号：EP11817649.4
申请日：2011-08-18
发明人： HUANG, Zhenhua , WANG, Jinyuan , ZHANG, Dedong
IPC分类号： A61K31/381 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/407 , A61K31/417 , C07D487/04 , C07D471/04 , A61K31/437 , A61K31/4745 , A61K31/4985 , A61K31/517 , A61K31/5365
-
公开(公告)号：EP2781508B1
公开(公告)日：2018-12-12
申请号：EP12850344.8
申请日：2012-11-16
发明人： ZHANG, Yan , ZHANG, Min , LO, HoYin
IPC分类号： C07D209/22 , C07D231/56 , C07D403/06 , C07D471/04 , A61K31/405 , A61K31/416 , A61K31/4162 , A61P11/06 , A61P37/00
CPC分类号： A61K31/405 , A61K31/416 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K45/06 , C07D209/14 , C07D209/22 , C07D231/56 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/12 , C07D471/04
摘要： The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X 1 , X 2 , X 3 , X 4 , X 5 , W, X, Y, L 1 , L 2 , L 3 , A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.
-
公开(公告)号：EP2781508B9
公开(公告)日：2019-08-21
申请号：EP12850344.8
申请日：2012-11-16
发明人： ZHANG, Yan , ZHANG, Min , LO, HoYin
IPC分类号： C07D209/22 , C07D231/56 , C07D403/06 , C07D471/04 , A61K31/405 , A61K31/416 , A61K31/4162 , A61P11/06 , A61P37/00
-
7.发明公开
公开(公告)号：EP3517113A1
公开(公告)日：2019-07-31
申请号：EP17852425.2
申请日：2017-09-22
发明人： HUANG, Zhenhua , GUO, Xiaocui
IPC分类号： A61K31/4745 , A61K47/00 , A61K9/00 , A61P13/12
摘要： Provided are a pharmaceutical composition comprising a mineralocorticoid receptor antagonist and use thereof. When the pharmaceutical composition is orally administered to a patient having chronic kidney disease in need thereof, the effective and safe AUC ranges from 188 ng ∗ h/mL to 3173 ng ∗ h/mL, with bioavailability of 50% or more in mammals. When the pharmaceutical composition is orally administered at a daily dose of 0.1 to 1.0 mg to treat chronic kidney disease, the AUC is controlled at a safe and effective level.
-
8.发明公开
公开(公告)号：EP2781508A4
公开(公告)日：2015-04-29
申请号：EP12850344
申请日：2012-11-16
IPC分类号： C07D209/22 , A61K31/405 , A61K31/416 , A61K31/4162 , A61P11/06 , A61P37/00 , C07D231/56 , C07D403/06 , C07D471/04
CPC分类号： A61K31/405 , A61K31/416 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K45/06 , C07D209/14 , C07D209/22 , C07D231/56 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/12 , C07D471/04
摘要： The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X 1 , X 2 , X 3 , X 4 , X 5 , W, X, Y, L 1 , L 2 , L 3 , A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.
-
9.发明公开NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS 有权STICKSTOFFHALTIGE KONDENSIERTE RINGVERBINDUNGEN ZUR VERWENDUNG ALS CRTH2-ANTAGONISTEN
公开(公告)号：EP2781508A1
公开(公告)日：2014-09-24
申请号：EP12850344.8
申请日：2012-11-16
发明人： ZHANG, Yan , ZHANG, Min , LO, HoYin
IPC分类号： C07D209/22 , C07D231/56 , C07D403/06 , C07D471/04 , A61K31/405 , A61K31/416 , A61K31/4162 , A61P11/06 , A61P37/00
CPC分类号： A61K31/405 , A61K31/416 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K45/06 , C07D209/14 , C07D209/22 , C07D231/56 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/12 , C07D471/04
摘要： The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X 1 , X 2 , X 3 , X 4 , X 5 , W, X, Y, L 1 , L 2 , L 3 , A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.
摘要翻译： 本申请涉及通式（I）所示的含氮稠环化合物，其药学上可接受的盐和其立体异构体作为CRTH2拮抗剂，其中X 1，X 2，X 3，X 4，X 5，W， X，Y，L 1，L 2，L 3，A，B如说明书中所定义; 本申请还涉及制备化合物的方法，药物制剂和包含该化合物的药物组合物，该化合物用于制备用于治疗和/或预防与CRTH2的活性有关的疾病的药物的用途。
-
公开(公告)号：EP2738156A1
公开(公告)日：2014-06-04
申请号：EP12817774.8
申请日：2012-07-26
发明人： ZHANG, Hui , DONG, Yanyan
IPC分类号： C07C235/66 , C07D205/04 , C07D205/12 , C07D209/54 , C07D209/52 , C07D221/20 , A61K31/65 , A61K31/337 , A61K31/397 , A61K31/40 , A61K31/403 , A61P3/10 , A61P31/00 , A61P35/00
CPC分类号： C07C237/26 , A61K31/65 , C07C231/12 , C07C2601/04 , C07C2602/40 , C07C2603/46 , C07C2603/94 , C07D205/04 , C07D205/12 , C07D209/52 , C07D209/54 , C07D221/20 , C07D221/22 , C07D305/06 , C07D491/107
摘要： The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease.
wherein, R 2a , R 2b , R 3 , R 4a , R 4b , R 5 , R 6a , R 6b , R 7 , R 8 , R 9a , R 9b , R 10 , R 11 , R 12 , R 13a and R 13b are each independently as defined in the description.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.019 秒)
